Abemaciclib in Focus: A Look at monarchE Trial Breast 12 Mins Read6 Abemaciclib, a CDK4 & 6 inhibitor, has shown a sustained benefit in invasive disease-free survival in high-risk EBC, as seen…
monarchE Trial Efficacy and Safety Results by Age in High-risk Early Breast Cancer Breast 3 Mins Read17 Erika Hamilton, MD, a preeminent expert from the Sarah Cannon Research Institute, has recently conducted a study evaluating the efficacy…
Abemaciclib: 2023 Kidney Cancer Breakthroughs Rana McKay, MD Slides Kidney 20 Mins Read8 Belzutifan and other Novel Therapies in Genitourinary Oncology 2023 By Rana McKay, MD – University of California San Diego We’re…
